RVNC News and Press, Revance Therapeutics Inc. From 01/06/23

- Prescription Drug User Fee Act (PDUFA) date of August 19, 2023 - Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® (Daxibotulinumtoxin...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 34 th Annual Piper Sandler Healthcare Conference, taking place November 29-December 1, 2022, in New ...

Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body. Research and development is still focused on trying t...

Nanostics Announces New Member of Board of Directors PR Newswire EDMONTON, AB , Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin...

Summary FDA approval of DAXXIFY for the treatment of patients with glabellar (frown) lines already obtained by Revance Therapeutics, Inc. A competing drug by the name of BOTOX was estimated to have generated more than $14.6 billion in sales in 2021. sBLA of DAXXIFY for the tre...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2022 Healthcare Conference, taking place November 15-16, 2022, in New York City. Chief Financial ...

Revance Therapeutics, Inc. (RVNC) Q3 2022 Results Conference Call November 08, 2022 04:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Finan...

Revance Therapeutics press release ( NASDAQ: RVNC ): Q3 GAAP EPS of -$1.17 misses by $0.23 . Revenue of $29M (+47.2% Y/Y) beats by $0.76M . 2022 Financial Outlook- Revance expects its 2022 GAAP and non-GAAP operating expenses to be on the upper end of its pre...

Received FDA approval for DAXXIFY ™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines Q3 total revenue of $29.0 million, a YoY increase of 47% with RHA ® Collection revenue of $26.1 million, a YoY increase of 43% Ae...

- Precise injection technique and comprehensive patient assessment can lead to optimized aesthetic outcomes when treating frown lines - Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial-stage biotechnology company focused on innovative aesthetic and therapeutic offerin...